Arakis is a private UK based biopharmaceutical company that discovers, develops and commercialises innovative medicinal products based on established drugs and drug templates. Its chosen therapeutic areas are inflammatory disease and oncology adjunctive therapy. Arakis has four products in clinical development: NVA237 for chronic obstructive pulmonary disease (COPD) and AD 452 for rheumatoid arthritis (RA) which have completed Phase IIa trials and AD 337 for fibromyalgia syndrome and AD 923 for cancer breakthrough pain (CBP) are in Phase I. In addition, there is a preclinical pipeline of other opportunities, two of which are finishing proof-of-principle studies. Arakis was founded in March 2000 and has raised over £49 million in three private equity funding rounds. The company is based at Chesterford Research Park, south of Cambridge, UK and currently has 38 employees.
| Website | http://www.arakis.com |
| Revenue | $10 million |
| Employees | View employees |
| Founded | 2000 |
| Phone | +44 20 7691 2081 |
| Industry | Biotechnology, Manufacturing General, Manufacturing, Science and Engineering, Drug Discovery, Pharmaceutical, Health Care |
| Competitors | Roche, Pfizer, Bristol Myers Squibb, AstraZeneca, Novartis, Gilead Sciences, Johnson & Johnson, Merck AH, Lilly India, Takeda +52 more (view full list) |
| SIC | SIC Code 2834 Companies, SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Arakis Ltd employee's phone or email?
Arakis Ltd Questions
The Arakis Ltd annual revenue was $10 million in 2026.
Arakis Ltd is based in Calgary, Alberta.
The NAICS codes for Arakis Ltd are [325, 32, 3254, 32541].
The SIC codes for Arakis Ltd are [2834, 28, 283].
